Is It Time To Think Beyond mRNA For COVID Vaccines? FDA Advisors Intrigued by Novavax As Booster

Many VRBPAC committee members said they were impressed with Novavax’s booster data, including with its prototype vaccine, raising questions about whether non-mRNA vaccine platforms may be preferable to address COVID long-term.

novavax covid prototype vax
Some FDA vaccine advisors suggested looking beyond mRNA vaccines for COVID-19 boosters. • Source: Shutterstock

Some of the US Food and Drug Administration’s vaccine advisors expressed interest in using Novavax, Inc.’s currently unauthorized protein-based COVID-19 vaccine, NVX-CoV2373, as a booster candidate this fall to help elicit broader protection against new and future SARS-CoV-2 variants.

They pushed the agency to think more broadly about the booster topic than the FDA seemed willing during the 28...

More from Vaccines

More from Pink Sheet